Evaluation of diagnostic performance of the "STANDARD G6PDTM" quantitative point-of-care test in neonates and infants

This study demonstrates that the "STANDARD G6PDTM" quantitative point-of-care test is a reliable and accurate tool for diagnosing G6PD deficiency in neonates and infants using cord and capillary blood up to one week of life, although longitudinal data indicates that G6PD activity naturally decreases over the first four months, potentially necessitating adjusted thresholds for interpreting intermediate results in female infants.

The Gist

Imagine a newborn baby's body is like a brand-new car factory. One of the most important workers in this factory is a tiny machine called G6PD. Its job is to protect the factory's red blood cells (the delivery trucks) from getting damaged.

Sometimes, a baby is born with a factory that has a "broken" or "weak" version of this machine. This is called G6PD Deficiency. If these babies are exposed to certain things (like specific medicines or even some foods), their delivery trucks can break down rapidly, causing a dangerous buildup of waste called bilirubin. This waste turns the baby yellow (jaundice) and, if it gets too high, can damage their brain.

The Problem:
Doctors need to know immediately if a baby has this broken machine so they can protect the baby. Usually, they test the baby's blood right at birth using a sample from the umbilical cord. But what if the baby is born at home, or the cord blood test isn't done? Can doctors test the baby's finger or heel blood a few days later and get the same answer?

Also, does the baby's "machine" work differently as the baby grows from a newborn to a 4-month-old?

The Study: A "Stress Test" for the New Machine
Researchers in Thailand decided to run a massive "stress test" to answer these questions. They used a special, portable handheld scanner called the "STANDARD G6PD" test. Think of this scanner like a smartphone app that can instantly tell you how well the factory machine is working.

Here is what they did:

1. The Setup: They found 75 babies. They tested them with the scanner on their umbilical cord blood right at birth.
2. The Groups: They sorted the babies into three groups based on the results:
   • The Broken Group (Deficient): The machine is broken.
   • The "Maybe" Group (Intermediate): The machine is half-broken (mostly in girls).
   • The Strong Group (Normal): The machine is working perfectly.
3. The Follow-up: They didn't just stop there. They tested these same babies again at:
   • 24 hours old (heel prick).
   • 7 days old.
   • 28 days old.
   • 4 months old.
4. The Gold Standard: To make sure their portable scanner was accurate, they also sent the blood to a fancy lab with a giant, expensive microscope (spectrophotometry) to check the results.

The Findings: What Did They Discover?

• The Scanner Works Great: The portable handheld scanner gave almost the exact same results as the giant lab machine. It's like having a high-quality smartphone camera that takes photos just as good as a professional studio camera.
• Timing Doesn't Matter (Much): The results from the umbilical cord (birth) were very similar to the results from the heel prick taken within the first 24 hours or even 7 days later.
  • Analogy: It's like checking the oil in a car right after it leaves the factory vs. checking it after it's driven 50 miles. The reading is consistent enough to know if the engine is healthy.
• The "Maybe" Group is Tricky: For babies with "intermediate" levels (mostly girls), the numbers changed a bit as they grew. The machine seemed to slow down slightly over the first few months. This means doctors might need to be extra careful when reading the results for these specific babies as they get older.
• The Numbers Drop: As the babies grew from 1 week to 4 months, the G6PD activity naturally went down a bit (about 20-30% lower). This is normal biology, like a runner slowing down after the first sprint.

Why This Matters
This study is a game-changer for places where hospitals are far away or resources are low.

• Before: If a baby was born at home and came in a week later with jaundice, doctors might have been unsure if the portable test was accurate for that age.
• Now: They know they can use this simple, cheap, handheld scanner on a baby's heel blood anytime in the first week of life. It's reliable.

The Bottom Line
The "STANDARD G6PD" test is a reliable tool. It allows doctors to quickly spot babies with a broken "factory machine" (G6PD deficiency) whether the test is done on the umbilical cord at birth or on a heel prick a few days later. This helps prevent brain damage from jaundice and ensures these babies don't get medicines that could hurt them. It's a simple tool that could save many lives in remote communities.

Technical Summary

Title

Evaluation of diagnostic performance of the "STANDARD G6PDTM" quantitative point-of-care test in neonates and infants.

1. Problem Statement

• Clinical Context: Severe neonatal hyperbilirubinaemia (NH) is a major cause of mortality and long-term neurological morbidity (kernicterus) in low-resource settings. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a primary risk factor for NH.
• Diagnostic Gap: While the "STANDARD G6PDTM" quantitative point-of-care (POC) test is validated for cord blood at birth, approximately 15% of neonates in the study setting are born outside clinics and are not tested until later (capillary blood within the first 24 hours or days).
• Knowledge Gap: It is unknown whether G6PD activity thresholds established for cord blood are equivalent to those for capillary blood collected in the first week of life. Furthermore, there is a lack of data on how G6PD activity changes longitudinally during the first month of life, a critical period for clinical decision-making regarding phototherapy and drug safety.

2. Methodology

• Study Design: Prospective observational cohort study conducted at the Shoklo Malaria Research Unit (SMRU) on the Thailand-Myanmar border.
• Participants: 75 neonates (39 females, 36 males) born to Karen and Burman mothers. Inclusion criteria included gestational age ≥35 weeks, no severe maternal/neonatal complications, and G6PD activity falling within deficient, intermediate, or normal ranges based on initial cord blood screening.
• Sampling Protocol:
  • Timepoints: Cord blood (birth), Capillary blood (<24 hours), Day 7, Day 28, and Month 4.
  • Total Samples: 295 follow-up samples analyzed.
• Diagnostic Tools:
  • POC Test: "STANDARD G6PDTM" (SD Biosensor, Korea) measuring activity in U/gHb.
  • Gold Standard: Reference spectrophotometric assay (Pointe Scientific kit) on a SHIMADZU UV-1800.
  • Supporting Data: Complete Blood Count (CBC), Hemocue 301+ for hemoglobin, and genotyping for G6PD mutations (Mahidol, Viangchan, etc.).
• Statistical Analysis:
  • Equivalence assessment via Pearson's correlation.
  • Agreement analysis using Intraclass Correlation Coefficient (ICC) and Bland-Altman plots.
  • Classification consistency checked against established thresholds: Deficient (≤4.8 U/gHb), Intermediate (4.9–9.9 U/gHb, females only), Normal (≥10.0 U/gHb).

3. Key Contributions

• Validation of Sample Type: The study provides the first evidence that the "STANDARD G6PDTM" test yields equivalent diagnostic results in cord blood and capillary blood collected within the first 24 hours and up to 7 days of life.
• Longitudinal Data: It maps the trajectory of G6PD activity in the first 4 months of life, confirming a physiological decline in enzyme activity over time.
• Threshold Verification: It validates that cord blood-derived thresholds can be safely applied to capillary blood for identifying G6PD-deficient males and homozygous/hemizygous females in the first week of life.

4. Key Results

• Diagnostic Equivalence (Cord vs. Capillary):
  • Correlation: High correlation between cord blood and <24h capillary blood (Pearson's r = 0.937 for Biosensor; r = 0.980 for spectrophotometry).
  • Classification Accuracy: All G6PD-deficient hemizygous males and homozygous females were correctly identified as deficient using cord blood thresholds in capillary samples up to Day 7.
  • Intermediate Females: While most were correctly identified, some heterozygous females with intermediate activity were misclassified when using cord thresholds on capillary blood at Day 7 (5 participants), suggesting thresholds may need adjustment for females after the first week.
• Longitudinal Trends:
  • Activity Decline: G6PD activity decreased significantly over time. By Day 28, activity dropped to ~70-80% of cord blood levels; by Month 4, it was ~75%.
  • Hemoglobin Influence: Early increases in White Blood Cells (WBC) and reticulocytes in the first 24 hours contributed to a transient increase in measured G6PD activity in deficient participants, followed by a decline.
• Test Performance vs. Gold Standard:
  • The Biosensor showed excellent agreement with spectrophotometry (ICC > 0.9).
  • Mean differences were small, though limits of agreement were wider at higher activity levels.
• Clinical Outcomes: Among neonates >38 weeks, G6PD-deficient and intermediate infants had a higher rate of requiring phototherapy compared to G6PD-normal infants.

5. Significance and Implications

• Clinical Utility: The "STANDARD G6PDTM" test is confirmed as a reliable tool for diagnosing G6PD deficiency in neonates using capillary blood up to one week of life. This allows for the extension of clinical management (e.g., avoiding hemolytic drugs, intensified bilirubin monitoring) to babies born outside clinics who miss cord blood testing.
• Low-Resource Settings: The portability and speed of the POC test make it ideal for primary care and mobile populations where laboratory spectrophotometry is unavailable.
• Limitations & Future Directions:
  • Female Thresholds: The study highlights a need for age-specific thresholds for heterozygous females, as activity levels drop and overlap with deficiency ranges after the first week.
  • Age Gap: The study only followed participants to 4 months. Since G6PD activity continues to decline until 1 year of age, the test's performance and appropriate thresholds for infants aged 4 months to 2 years remain a diagnostic gap, particularly for the safe administration of 8-aminoquinoline antimalarials.

Conclusion: The study confirms that the "STANDARD G6PDTM" test can effectively support clinical care for neonates with G6PD deficiency in low-resource settings using capillary blood within the first week of life, provided that specific attention is paid to the interpretation of intermediate results in female infants over time.